2d illustrations and photos Jefferies, Citi, Guggenheim and Morgan Stanley started coverage of Zenas BioPharma ( NASDAQ: ZBIO ) with bullish ratings, citing the potential of its lead autoimmune drug candidate, obexelimab. Jefferies initiated coverage of Zenas ( ZBIO ) with a buy rating and price target of $35. The.
